biostudies-literatureDelmonte ABristol Myers Squibb538https://www.ebi.ac.uk/biostudies/studies/S-EPMC12897191biostudies-literatureUnknown18(3)Background: Treatment for advanced non-small-cell lung cancer (NSCLC) has evolved substantially over the past decade, necessitating evaluation of real-world treatment patterns and effectiveness before and after the introduction of newer therapies. Methods: This retrospective cohort study included adult patients initiating a non-curative first-line therapy for advanced NSCLC between 2014 and 2021 at the IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), with follow-up through 2022. Overall survival (OS) and real-world progression-free survival from the start date of the first line of therapy for advanced NSCLC were estimated using Kaplan-Meier methods. Results: Overall, 910 patients were included; at diagnosis, 83% had a de novo diagnosis and 17% had recurrent diCancersReal-World Treatment Patterns and Survival in Patients with Advanced Non-Small Cell Lung Cancer: An Italian Retrospective Cohort Study.PMC12897191N/AHindocha PDelmonte ADanesi VMassa IMaltoni RLeal CGlassberg MBMella MEmanuel GLay-Flurrie SLee ARoncadori ARault CGentili NOikonomou SYuan YfalseReal-World Treatment Patterns and Survival in Patients with Advanced Non-Small Cell Lung Cancer: An Italian Retrospective Cohort Study.Background: Treatment for advanced non-small-cell lung cancer (NSCLC) has evolved substantially over the past decade, necessitating evaluation of real-world treatment patterns and effectiveness before and after the introduction of newer therapies. Methods: This retrospective cohort study included adult patients initiating a non-curative first-line therapy for advanced NSCLC between 2014 and 2021 at the IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), with follow-up through 2022. Overall survival (OS) and real-world progression-free survival from the start date of the first line of therapy for advanced NSCLC were estimated using Kaplan-Meier methods. Results: Overall, 910 patients were included; at diagnosis, 83% had a de novo diagnosis and 17% had recurrent di2026-01-01T00:00:00Z2026 Feb2026-07-07T03:16:30.812Z2026-07-07T03:08:46.958ZS-EPMC128971914168200810.3390/cancers18030538